EICHORCondition: Metabolic Dysfunction-Associated Steatohepatitis (MASH) · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Sponsor: Eli Lilly and Company
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Blood tests and magnetic resonance imaging of the liver will be performed to determine the effects of LY3849891 on MASLD and assessment of resolution of liver fibroinflammation. Blood tests will also determine how long it takes the body to eliminate LY3849891. This is a 2-part study and may last up to 32 weeks for each participant and may include 12 visits in parts A and B.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Arizona Liver Health - Chandler | Chandler, Arizona, United States | — |
| Orange County Research Center | Orange, California, United States | — |
| Inland Empire Clinical Trials, LLC | Rialto, California, United States | — |
| Synergy Healthcare LLC | Brandon, Florida, United States | — |
| Accel Research Sites - Maitland | Maitland, Florida, United States | — |
| Evolution Clinical Trials, Inc | Miami, Florida, United States | — |
| Advanced Pharma Clinical Research | Miami, Florida, United States | — |
| Floridian Clinical Research | Miami Lakes, Florida, United States | — |
| Charter Research - Winter Park | Orlando, Florida, United States | — |
| IU Health University Hospital | Indianapolis, Indiana, United States | — |
| Houston Research Institute | Houston, Texas, United States | — |
| Clinical Trials of Texas, Inc. | San Antonio, Texas, United States | — |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05395481